Amarin Q2 2023 Earnings Report $0.59 0.00 (-0.82%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Amarin EPS ResultsActual EPS-$0.04Consensus EPS -$0.04Beat/MissMet ExpectationsOne Year Ago EPSN/AAmarin Revenue ResultsActual Revenue$80.17 millionExpected Revenue$73.40 millionBeat/MissBeat by +$6.77 millionYoY Revenue GrowthN/AAmarin Announcement DetailsQuarterQ2 2023Date8/2/2023TimeN/AAMRN Upcoming EarningsAmarin will be holding an earnings conference call on Wednesday, March 12 at 8:00 AM Eastern. Interested parties can register for or listen to the call or dial in at 919-882-2331 using passcode "51859". Conference Call ResourcesPress ReleaseAMRN Earnings HistoryPowered by Amarin Earnings HeadlinesAmarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025February 19 at 8:30 AM | globenewswire.comFY2025 EPS Estimates for Amarin Decreased by Zacks ResearchFebruary 15, 2025 | americanbankingnews.com$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.February 22, 2025 | Altimetry (Ad)Amarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.comFebruary 13, 2025 | americanbankingnews.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for WeekJanuary 24, 2025 | msn.comAmarin Receives National Reimbursement for VAZKEPA® in ItalyDecember 16, 2024 | globenewswire.comSee More Amarin Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amarin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amarin and other key companies, straight to your email. Email Address About AmarinAmarin (NASDAQ:AMRN), a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.View Amarin ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
